Cibinqo (Abrocitinib) Patent Expiration, LOE Window & CMS Spending

Cibinqo (Abrocitinib) by Pfizer: FDA Orange Book core substance LOE 2036-01-14, 0 AB generics, $38.7M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN213871 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-01-14
Last Listed Patent or Exclusivity Date2036-01-14
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$38.7M
2024 Medicare Part D Spend$17.1M
2024 Medicaid Spend$21.6M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 19.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.